Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02351739
Title Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer
Acronym KEYNOTE143
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Acerta Pharma BV
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Chicago Chicago Illinois United States Details
University of Michigan Ann Arbor Michigan United States Details
Durham North Carolina United States Details
James Cancer Hospital Columbus Ohio United States Details
Oregon Health and Science University Portland Oregon United States Details
University of Pittsburgh Pittsburgh Pennsylvania United States Details
Carolina Urologic Research Center Myrtle Beach South Carolina United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field